The consensus that drug manufacturers are at fault for high prescription prices comes even though only half the respondents said they were taking medication themselves.
Drug prices are far too high and most Americans put the blame squarely on the companies that make them, according to the most recent Kaiser Health Tracking poll.
Released today, the poll found that 73% of the public find the cost of prescription drugs “unreasonable.” In this group, 76% said pharmaceutical companies charge too much for prescriptions, while another 10% say the blame rests jointly on drug manufacturers and insurance companies.
Another 10% say consumers pay too much for drugs because insurance companies charge too much.
The cost of prescription drugs is both a consumer issue and a public health concern, because studies have consistently linked high out-of-pocket costs with poor medication adherence; in turn, the latter is blamed for unnecessary emergency department visits and high hospital costs. A study presented just last week at the American Diabetes Association found that increased co-payments led to poor adherence and higher medical costs among Medicare patients with type 2 diabetes mellitus.
The Kaiser Health Tracking Poll, conducted most months by the Kaiser Family Foundation since April 2010, also tracks public opinion on the Affordable Care Act. The poll found 39% had a favorable view of the law, while 42% had an unfavorable view, with opinion sharply divided by party registration. Over time, the numbers viewing the poll favorably have shifted from month to month, but the overall divide and the ideological split have remained intact.
The wide margin of Americans who see high drug costs as a problem—and who blame drug manufacturers—comes even though only half of the respondents said they were taking prescription medication themselves. Of those who take medication, 76% said they can afford it, but 21% said paying for it is difficult. One quarter—25%—reported that they or a family member did not fill a prescription in the past year due to cost, while 18% reported cutting pills in half or skipping doses to save money.
While there was a consensus to pin blame on drug manufacturers for high prices, respondents were divided on underlying causes: 77% cited company profits, 54% listed marketing and advertising, and 49% blamed the cost of lawsuits against drug companies.
Respondents were equally split on what to do about the problem. Just over half (53%) said drug prices did not have enough regulation, while 12% said there is too much, and 28% said the level of regulation is about right. The ideological divide showed up here, too: Republicans were more likely than Democrats to say there was too much government regulation (19% to 8%).
KFF conducted the poll from June 2-9, 2015, among a nationally representative sample of 1200 adults.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More